BiotechTube
Proteowise

Proteowise

San Francisco, United States· Est.
proteowise.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ProteoWise is a private, pre-revenue platform company targeting the proteomics research tools market with its Hyperblot instrument. The technology, based on proprietary 3D-NPC, automates western blot-style analysis to enable unlimited-plex, quantitative protein measurement from minimal sample volumes in a single run. With a seasoned leadership team and backing from strategic life science investors, the company is positioned to address a significant bottleneck in biomedical research, though it faces competition from established and emerging proteomic technologies. Its success hinges on commercial execution, platform validation, and market adoption against entrenched methods.

ProteomicsAI / Machine Learning

Technology Platform

Hyperblot instrument utilizing proprietary 3D-NPC technology for automated, unlimited-plex, quantitative western blot-style protein analysis from minimal sample volume.

Opportunities

The global shift towards precision medicine and functional biology creates a large, growing demand for accessible high-plex proteomics.
Replacing the entrenched but inefficient western blot market represents a multi-billion dollar opportunity.
Strategic partnerships with reagent companies can accelerate market penetration and create a sticky consumables business.

Risk Factors

The platform must deliver technically robust performance to overcome researcher skepticism and displace established methods.
The company faces intense competition from both legacy immunoassay companies and novel proteomic startups.
As a pre-revenue tools company, commercial execution and scaling manufacturing and support are significant challenges.

Competitive Landscape

ProteoWise competes with traditional western blotting, multiplex immunoassay platforms (e.g., Luminex, MSD, Olink), and high-end mass spectrometry. Its key differentiator is the promise of unlimited plex on a familiar benchtop format. However, it must contend with the deep market penetration, validation, and trust enjoyed by these established technologies.

More companies in United States →